S-1: InMed Pharmaceuticals Files for Resale of 3 Million Common Shares Under Standby Equity Agreement

InMed Pharmaceuticals has filed a registration statement for the potential resale of up to 3 million common shares by a selling shareholder, following a Standby Equity Purchase Agreement.

Summary

• InMed Pharmaceuticals has filed a registration statement for the resale of up to 3,000,000 common shares.
• These shares may be sold by a selling shareholder, YA II PN, LTD, following a Standby Equity Purchase Agreement (SEPA) dated December 13, 2024.
• The company may receive up to $10,000,000 in gross proceeds from sales of common shares to the selling shareholder under the SEPA.
• InMed will not receive any proceeds from the resale of shares by the selling shareholder.
• The selling shareholder is considered an underwriter and may sell the shares at varying prices.
• The company's common shares are listed on the Nasdaq Capital Market under the symbol INM.
• As of December 20, 2024, the last reported sale price of InMed's common shares was $4.40 per share.
• InMed is an emerging growth company and a smaller reporting company, subject to reduced reporting requirements.
• The company has incurred significant operating losses and expects to continue to do so.
• InMed's net loss was $7.7 million for the year ended June 30, 2024, and $7.9 million for the year ended June 30, 2023.
• The company has an accumulated deficit of $109.1 million as of June 30, 2024.
• InMed expects expenses to remain steady as they advance research programs, seek regulatory approvals, and scale manufacturing.
• The company will need substantial additional funding to support operations and growth.
• InMed may finance operations through product sales, equity, debt, or strategic collaborations.
• The company may have to delay or discontinue development if it cannot raise sufficient capital.
• On November 14, 2024, InMed effected a 20-for-1 reverse stock split.
• The company has regained compliance with Nasdaq's minimum bid price rule as of December 2, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has a potential funding source through the SEPA and has regained Nasdaq compliance, it also faces significant financial challenges, including substantial losses and an accumulated deficit. The reliance on future capital raises and the potential for dilution create uncertainty.

Positives

• InMed has a Standby Equity Purchase Agreement in place that could provide up to $10 million in funding.
• The company has regained compliance with Nasdaq's minimum bid price rule, ensuring continued listing.
• InMed has a pipeline of drug candidates targeting Alzheimer's disease, dry age-related macular degeneration, and Epidermolysis Bullosa.
• The company has multiple manufacturing approaches, including a proprietary integrated approach called IntegraSyn.

Negatives

• InMed has incurred significant operating losses and expects to continue to do so.
• The company has an accumulated deficit of $109.1 million.
• The company is dependent on raising additional capital to fund operations and growth.
• The selling shareholder may sell shares at varying prices, potentially impacting the market price.
• The company may not receive the full $10 million under the SEPA due to limitations and market conditions.
• The resale of shares by the selling shareholder could cause dilution and depress the market price of the common shares.

Risks

• The company may not be able to raise sufficient capital to fund operations.
• The selling shareholder's sales could depress the market price of InMed's common shares.
• The company's share price could be highly volatile.
• There is a risk of dilution to existing shareholders from the sale of shares under the SEPA.
• The company's management has broad discretion over the use of proceeds from the sale of shares.
• The selling shareholder will purchase shares at a discount, which could cause the share price to decline.
• The company may not have access to the full amount under the SEPA if the share price decreases.
• A change of control could occur if the company continues to make drawdown requests while the selling shareholder holds shares.
• Delisting from Nasdaq could materially and adversely affect the company's ability to raise additional financing.
• The company's ability to achieve profitability is uncertain.

Future Outlook

The company expects to continue to incur operating losses and will need substantial additional funding to support its operations and growth strategy. They plan to finance operations through product sales, equity, debt, or strategic collaborations. The company is also pursuing strategic partnership opportunities for INM-755 in EB and other itch-related skin conditions.

Management Comments

• Management will have broad discretion with respect to the use of proceeds from the sale of any common shares to the Selling Shareholder.
• Management believes that their manufacturing approaches are robust and effective and will result in commercially viable yields of cannabinoids.

Industry Context

The document highlights InMed's focus on developing cannabinoid-based therapeutics, which aligns with the growing interest in the pharmaceutical and health and wellness sectors for such compounds. The company's focus on rare cannabinoids and proprietary manufacturing methods positions it within a niche market that is gaining traction.

Comparison to Industry Standards

• InMed's focus on developing novel cannabinoid-based therapeutics is similar to other companies in the biotechnology and pharmaceutical space, such as GW Pharmaceuticals (now part of Jazz Pharmaceuticals) which developed Epidiolex, a CBD-based drug.
• The company's research into Alzheimer's disease and age-related macular degeneration places it in competition with larger pharmaceutical companies that are also developing treatments for these conditions, such as Biogen and Regeneron.
• The company's manufacturing capabilities, including IntegraSyn, are aimed at improving the cost-effectiveness and scalability of cannabinoid production, which is a common challenge in the industry.
• The company's financial situation, with significant operating losses and an accumulated deficit, is not uncommon for clinical-stage pharmaceutical companies that are heavily reliant on research and development.

Related Party Transactions

• Norton Rose Fulbright Canada LLP and Norton Rose Fulbright US LLP provided legal services to the company, with fees of $226,793 in 2024 and $634,208 in 2023.

Stakeholder Impact

• Shareholders face the risk of dilution and potential decline in share price due to the sale of shares under the SEPA.
• Employees may be impacted by the company's financial instability and potential need to reduce or terminate operations.
• Customers of BayMedica may be affected by the company's ability to maintain and scale its manufacturing operations.
• Suppliers and creditors may be impacted by the company's financial situation and ability to meet its obligations.

Next Steps

• The company will continue to advance research with proprietary drug candidates.
• InMed will seek regulatory approvals for any Product Candidates that successfully complete clinical trials.
• The company will scale-up manufacturing processes and capabilities.
• InMed will continue to support commercial operations and revenue-generating Products at BayMedica.
• The company will execute on business development activities, including strategic transactions, mergers, acquisitions and/or divestitures.
• InMed will maintain, expand, enforce, defend and protect its intellectual property.
• The company will continue to further advance the research and development of various manufacturing technologies.

Key Dates

Keywords

InMed Pharmaceuticals, common shares, Standby Equity Purchase Agreement, SEPA, resale, capital raise, Nasdaq, reverse stock split, drug development, cannabinoids, emerging growth company, smaller reporting company